William G. Wierda, M.D., Ph.D.

Peer-Reviewed Articles

1. Gopalakrishnan S, Wierda W, Chyla B, Menon R, Miles D, Humerickhouse R, Awni W, Salem AH, Mensing S, Freise KJ. Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia. Clin Pharmacol Ther 109(2):424-432, 2021. e-Pub 2020. PMID: 32749675.
2. Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
3. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. Acta Haematol 144(2):1-13, 2021. e-Pub 2020. PMID: 32392559.
4. Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma 61(13):1-8, 2020. e-Pub 2020. PMID: 32755333.
5. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
6. Frei M, Aitken SL, Jain N, Thompson P, Wierda W, Kontoyiannis DP, DiPippo AJ. Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. Leuk Lymphoma 61(10):1-4, 2020. e-Pub 2020. PMID: 32530347.
7. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien S. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clin Cancer Res 26(15):3918-3927, 2020. e-Pub 2020. PMID: 32209572.
8. Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, Keating MJ, Wierda WG, Long JP, Bertilaccio MTS, Gandhi V. AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia. Clin Cancer Res 26(14):3856-3867, 2020. e-Pub 2020. PMID: 31937611.
9. Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol 95(7):734-739, 2020. e-Pub 2020. PMID: 32170867.
10. Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia 34(6):1588-1598, 2020. e-Pub 2019. PMID: 31862959.
11. Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Smedby KE, Spina V, Bruscaggin A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillessen S, Ghielmini M, Cavalli F, Stussi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foà R, Pospisilova S, Morabito F, Stilgenbauer S, Döhner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi D. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood 135(21):1859-1869, 2020. PMID: 32267500.
12. Wierda WG, Tambaro FP. How I manage CLL with venetoclax-based treatments. Blood 135(17):1421-1427, 2020. PMID: 32076705.
13. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 395(10232):1278-1291, 2020. PMID: 32305093.
14. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv 4(8):1690-1699, 2020. PMID: 32330243.
15. Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Burke K, Covey T, Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, O'Brien S, Furman RR. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood 135(15):1204-1213, 2020. PMID: 31876911.
16. Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty generated CD19specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood 135(11):862-865, 2020. e-Pub 2020. PMID: 31961918.
17. Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving Complete Remission in CLL Patients Treated with Ibrutinib: Clinical Significance and Predictive Factors. Blood 135(7):510-513, 2020. e-Pub 2020. PMID: 31895947.
18. Shah M, Rajha E, DiNardo C, Muckey E, Wierda WG, Yeung SJ. Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know. Ann Emerg Med 75(2):264-286, 2020. e-Pub 2019. PMID: 31561995.
19. Alfayez M, Thakral B, Jain P, Ravandi F, Ferrajoli A, Jain N, Pemmaraju N, Wierda W, Kadia T. First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). Leuk Lymphoma 61(2):445-449, 2020. e-Pub 2019. PMID: 31566032.
20. Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol 95(2):144-150, 2020. e-Pub 2019. PMID: 31682008.
21. Tambaro FP, Wierda WG. Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. Lancet Haematol 7(2):e168-e176, 2020. PMID: 32004486.
22. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar H. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(2):185-217, 2020. PMID: 32023533.
23. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. PMID: 32023374.
24. Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol 11(1):19-23, 2020. e-Pub 2019. PMID: 31005650.
25. Chen LS, Keating MJ, Wierda WG, Gandhi V. Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells. Leuk Lymphoma 60(12):1-4, 2019. e-Pub 2019. PMID: 31161836.
26. Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Scarfò L, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris-Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS. Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. Cancer Immunol Res 7(12):2036-2051, 2019. e-Pub 2019. PMID: 31530560.
27. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol 203(11):3078-3085, 2019. e-Pub 2019. PMID: 31645416.
28. Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, Furman RR, Heffner L, Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC. Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica 104(11):2258-2264, 2019. e-Pub 2019. PMID: 30923097.
29. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
30. Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien S. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 134(21):1811-1820, 2019. PMID: 31558467.
31. Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood 134(22):1951-1959, 2019. PMID: 31537528.
32. Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol 187(1):e1-e4, 2019. e-Pub 2019. PMID: 31344256.
33. Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS, Biran A, Fernandes SM, Brown JR, Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG, Neuberg D, Harper JW, Carr SA, Piccioni F, Ott CJ, Leshchiner I, Johannessen CM, Doench J, Mootha VK, Getz G, Wu CJ. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell 36(4):369-384.e13, 2019. e-Pub 2019. PMID: 31543463.
34. Boddu P, Schlette E, Thakral B, Tang G, Pemmaraju N, Kadia T, Ferrajoli A, Ravandi F, Wierda W, Jain N. Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report. Hematol Oncol Stem Cell Ther 12(3):161-165, 2019. e-Pub 2017. PMID: 28830803.
35. Yalniz FF, Wierda WG. Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies. Drugs 79(12):1287-1304, 2019. PMID: 31313099.
36. Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood 134(8):688-698, 2019. e-Pub 2019. PMID: 31292113.
37. Chen R, Zhu M, Chaudhari RR, Robles O, Chen Y, Skillern W, Qin Q, Wierda WG, Zhang S, Hull KG, Romo D, Plunkett W. Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. Leukemia 33(7):1663-1674, 2019. e-Pub 2019. PMID: 30700841.
38. Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol 186(1):184-188, 2019. e-Pub 2019. PMID: 30740654.
39. Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood 134(2):111-122, 2019. e-Pub 2019. PMID: 31023700.
40. Wierda WG, Byrd JC, Davids MS, Furman RR, Cheson BD, Barr PM, Eradat H, Heffner L, Zhou L, Verdugo M, Potluri J, Choi M. Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. Br J Haematol 185(5):961-966, 2019. e-Pub 2018. PMID: 30478940.
41. Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
42. Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood 133(26):2765-2775, 2019. e-Pub 2019. PMID: 30862645.
43. Paul S, Jain N, Ferrajoli A, O'Brien S, Burger J, Keating M, Wierda W. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol 185(3):606-608, 2019. e-Pub 2018. PMID: 30406944.
44. Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol 109(5):545-552, 2019. e-Pub 2019. PMID: 30830579.
45. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 3(9):1533-1539, 2019. PMID: 31076409.
46. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. PMID: 31141631.
47. Wierda WG. Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?. Clin Adv Hematol Oncol 17(4):214-216, 2019. PMID: 31188811.
48. Cervantes-Gomez F, Stellrecht CM, Ayres ML, Keating MJ, Wierda WG, Gandhi V. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells. Oncotarget 10(29):2793-2809, 2019. e-Pub 2019. PMID: 31073371.
49. Boddu P, Thakral B, Alhuraiji A, Pemmaraju N, Kadia T, Ohanian M, Ravandi F, Jabbour E, Wierda W, Khoury JD, Jain N. Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation. J Clin Pathol 72(3):251-257, 2019. e-Pub 2018. PMID: 30467242.
50. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 133(10):1011-1019, 2019. e-Pub 2018. PMID: 30530801.
51. Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol 6(2):e100-e109, 2019. PMID: 30709431.
52. Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer 125(4):559-574, 2019. e-Pub 2018. PMID: 30508305.
53. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. J Natl Compr Canc Netw 17(1):12-20, 2019. PMID: 30659125.
54. Wierda W, Kipps T, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabham S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell C, Osterborg A.. Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine-and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab. Clin Lymphoma Myeloma 9(6):E36, 2009. PMID: 19951868.
55. Motta M, Wierda WG, Ferrajoli A. Chronic lymphocytic leukemia: treatment options for patients with refractory disease. Cancer 115(17):3830-41, 2009. e-Pub 2009. PMID: 19536902.
56. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M.. Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment. J Clin Oncol 27(10):1637-43, 2009. e-Pub 2009. PMID: 19224852.
57. Wierda W. New prognostic factors in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 7(1):32-42, 2009. PMID: 19274038.
58. Tam CS, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou AM, Kantarjian H, Wierda WG. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 48(10):1931-1939, 2007. PMID: 17917961.
59. Wierda W, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do K-A, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M.. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109(11):4679-4685, 2007. e-Pub 2007. PMID: 17299097.
60. Wierda WG, Kipps J. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol 20(3):557-68, 2007.
61. Wierda W, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106(2):337-45, 2006. PMID: 16353201.
62. Keating MJ, Rai KR, Wierda WG. Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-Part series: Advances in the treatment of hematologic malignancies. Clin Adv Hematol Oncol 3(8):1-10; quiz 11-2, 2005. PMID: 16201050.
63. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23(18):4070-4078, 2005. e-Pub 2005. PMID: 15767647.
64. Wierda WG, Keating MJ, O’Brien S. Refractory chronic lymphocytic leukemia – prognosis and treatment options. Am J Cancer 3(3):163-178, 2004.

Abstracts

1. Sharman JP, Banerji V, Fogliatto LM, Herishanu Y, Munir T, Walewska R, Follows G, Karlsson K, Ghia P, Corbett G, Walker P, Egyed M, Jurczak W, Salles G, Janssens A, Cymbalista F, Wierda WG, Coutre S, Pagel JM, Skarbnik A, Kamdar M, Woyach J, Izumi R, Munugalavadla V, Patel P, MH Wang, , Wong S, Byrd JC. ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement 1):31, 2019.
2. Short NJ, Kantarjian HM, Ravandi F, Huang X, Jain N, Sasaki K, Khouri R , Daver NG, Pemmaraju N, Khoury JD, Jorgensen JL, , Alvarado Y, Konopleva MY, Garcia-Manero G, Kadia TM, Yilmaz ME, Borthakur GM, Burger JA, Kornblau SM, Wierda WG, DiNardo CD, Ferrajoli A, Jacob J, Rostykus M, Garris R, Ward M, Huang B, Encarnacion C, Loiselle C, O'Brien SM, Jabbour E. Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood 134(Supplement 1):823, 2019.
3. William G. Wierda, MD PhD , Seung Tae Lee, MD PhD , Rong Chen, PhD , Daniella Zheleva, PhD , David Blake, PhD , Judy H Chiao, MD , William Plunkett, PhD. A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement 1):1761, 2019.
4. Koji Sasaki, MD , Hagop M. Kantarjian, MD , Elias Jabbour, MD , Farhad Ravandi, MD , Marina Y Konopleva, MD PhD , Gautam M. Borthakur, MD , <b>William G. Wierda, MD PhD</b> , Naval G. Daver, MD , Koichi Takahashi, MD , Kiran Naqvi, MDMPH , Courtney D. DiNardo, MDMSc , Guillermo Montalban Bravo, MD , Rashmi Kanagal-Shamanna, MD , Naveen Pemmaraju, MD , Ghayas C. Issa, MD , Preetesh Jain, MBBS,MDDM,PhD , Jeffrey Skinner, MHA , Mary B. Rios, RN , Sherry A. Pierce, BSN, BA , Kelly Soltysiak, PhD , Junya Sato , Guillermo Garcia-Manero, MD , Jorge E. Cortes, MD. The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood 134(Supplement 1):1642, 2019.
5. Jeff P. Sharman, MD, Versha Banerji, MD, Laura Maria Fogliatto, MD PhD, Yair Herishanu, MD, Talha Munir, MD, Renata Walewska, George Follows, Karin Karlsson, MD, Paolo Ghia, MD PhD, Gillian Corbett, Patricia Walker, MBBS, Miklos Egyed, Wojciech Jurczak, MD PhD, Gilles Salles, MD PhD, Ann Janssens, Florence Cymbalista, MD PhD, William Wierda, MD,PhD, Steven Coutre, MD, John M. Pagel, MD PhD DSc, Alan Skarbnik, MD, Manali Kamdar, MD, Jennifer Woyach, MD, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Priti Patel, MD, Min Hui Wang, PhD, Sofia Wong, John C. Byrd, MD. Expansion of T Helper Cell Subsets in Chronic Lymphocytic Leukemia Cell Co-Cultures with Nurselike Cells. Blood 134(Supplement 1):1746, 2019.
6. Michael Y. Choi, MD , Emanuela M. Ghia, PhD , Tanya Siddiqi, MD , William G. Wierda, MD PhD , Hun Ju Lee , Jacqueline C. Barrientos, MD MS , Nicole Lamanna, MD , Alec Goldenberg , Dimitrios Tzachanis, MD PhD , Erin G. Reid, MD MS , Elizabeth K Weihe, MD , Laura Z. Rassenti, PhD , Iris Isufi, MD , Stewart Bieler, BA , Xen Ianopulos, MD PhD , James B. Breitmeyer, MD PhD , Catriona Jamieson, MD PhD , Thomas J. Kipps, MD PhD. Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL. Blood 134(Supplement 1):1755, 2019.
7. Anthony R. Mato, MDMSCE , Kavita Sail, PhD , Maryam Sarraf Yazdy, MD , Brian T. Hill, MD , Mazyar Shadman, MD MPH , Beenish S Manzoor, PhD , Hande H. Tuncer, MD , John N. Allan, MD , Chaitra S. Ujjani, MD , Simon Sharmokh, MPH, PharmD , Daniel Dingfeng Jiang, MD PhD , German Pena, MD , Thomas Marshall, PharmD, MS , Jacqueline Nielsen, PhD , Paul M. Barr, MD , Jennifer R. Brown, MD PhD , Anna Schuh, PhD , Toby A. Eyre, MD , William G. Wierda, MD PhD , Alan Skarbnik, MD , Lindsey E. Roeker, MD , Rajat Bannerji, MD PhD , James M. Pauff, MD PhD , Stephen J. Schuster, MD , George A Follows, MD PhD , Bruce D. Cheson, MD , Barbara F. Eichhorst, MD , Danielle M. Brander, MD , Irina Pivneva, PhD , Nicole Lamanna, MD. Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies. Blood 134(Supplement 1):1756, 2019.
8. Nitin Jain, MD , Michael J Keating, MBBS , Philip A. Thompson, MBBS , Alessandra Ferrajoli, MD , Jan A. Burger, MD PhD , Gautam M. Borthakur, MD , Koichi Takahashi, MD , Zeev E. Estrov, MD , Nathan H. Fowler, MD , Tapan M. Kadia, MD , Marina Y Konopleva, MD PhD , Yesid Alvarado, MD , Musa Yilmaz, MD , Courtney D. DiNardo, MDMSc , Prithviraj Bose, MD , Maro Ohanian, DO , Naveen Pemmaraju, MD , Elias Jabbour, MD , Koji Sasaki, MD , Rashmi Kanagal-Shamanna, MD , Keyur Patel, MD PhD , Jeffrey L. Jorgensen, MD PhD , Sa A Wang, MD , Naveen Garg, MD , Xuemei Wang, MS , Katrina Sondermann, BA , Nichole Cruz, RN , Chongjuan Wei, PhD , Ana Ayala, RN , William Plunkett, PhD , Hagop M. Kantarjian, MD , Varsha Gandhi, PhD , William G. Wierda, MD PhD. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement 1):34, 2019.
9. Tanya Siddiqi, MD , Jacob D. Soumerai, MD , Kathleen A. Dorritie, MD , Deborah M. Stephens, DO , Peter A. Riedell, MD , Jon E. Arnason, MD , Thomas J. Kipps, MD PhD , Heidi H. Gillenwater, MD , Lucy Gong, PharmD , Jason A. Dubovsky, PhD , Julie Rytlewski, PhD , Lin Yang , William G. Wierda, MD PhD. Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib. Blood 134(Supplement 1):503, 2019.
10. Vivian M. Liu, MD , Romain Guièze, MD , Daniel Rosebrock , Alexis A Jourdain, PhD , María Hernández-Sánchez, PhD , Aina Zurita Martinez , Elisa Ten Hacken, PhD , Philip A. Thompson, MBBS , Julian Bryan Iorgulescu, MD PhD , Shuqiang Li, PhD , Matthew S. Davids, MD , Jennifer R. Brown, MD PhD , Ana Lako , Zoe B. Ciantra , Matthew A. Lawlor , William G. Wierda, MD PhD , Anthony G. Letai, MD PhD , Donna S Neuberg, ScD , Christopher J. Ott, PhD , Ignaty Leshchiner, PhD , Vamsi Mootha, MD , Gad Getz, PhD , Catherine J. Wu, MD. MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers. Blood 134(Supplement 1), 2019.
11. Jeff P. Sharman, MD, Versha Banerji, MD, Laura Maria Fogliatto, MD PhD, Yair Herishanu, MD, Talha Munir, MD, Renata Walewska, George Follows, Karin Karlsson, MD, Paolo Ghia, MD PhD, Gillian Corbett, Patricia Walker, MBBS, Miklos Egyed, Wojciech Jurczak, MD PhD, Gilles Salles, MD PhD, Ann Janssens, Florence Cymbalista, MD PhD, William Wierda, MD,PhD, Steven Coutre, MD, John M. Pagel, MD PhD DSc, Alan Skarbnik, MD, Manali Kamdar, MD, Jennifer Woyach, MD, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Priti Patel, MD, Min Hui Wang, PhD, Sofia Wong, John C. Byrd, MD. Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs). Blood 134(Supplement 1):1296, 2019.
12. Musa Yilmaz, MD , Hagop M. Kantarjian, MD , Xuemei Wang, MS , Joseph D. Khoury, MD , Farhad Ravandi, MD , Jeffrey L. Jorgensen, MD PhD , Nicholas J. Short, MD , Sanam Loghavi, MD , Jorge E. Cortes, MD , Guillermo Garcia-Manero, MD , Tapan M. Kadia, MD , Koji Sasaki, MD , Marina Y Konopleva, MD PhD , Koichi Takahashi, MD , William G. Wierda, MD PhD , Nitin Jain, MD , Srdan Verstovsek, MD PhD , Zeev E. Estrov, MD , Prithviraj Bose, MD , Sherry A. Pierce, BSN, BA , Rebecca Garris, MSc , Susan M. O'Brien, MD , Elias Jabbour, MD. The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong Predictor for Survival. Blood 134(Supplement 1):1297, 2019.
13. Constantine S. Tam, MBBS, MD , Tanya Siddiqi, MD , John N. Allan, MD , Thomas J. Kipps, MD PhD , Ian W. Flinn, MD PhD , Bryone J. Kuss, MBBS, PhD FRACP, FRCPA , Stephen Opat , Paul M. Barr, MD , Alessandra Tedeschi, MD , Ryan Jacobs, MD , Xavier C. Badoux, MBBS, FRACP, FRCPA , Paolo Ghia, MD PhD , Juthamas Sukbuntherng, PhD , Ahmed Hamed Salem, PhD FCP , Kristin Russell, BS , Karl Eckert, BA , Cathy Zhou, MS , Joi Ninomoto, PharmD , Danelle F. James, MD MAS , William G. Wierda, MD PhD. Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. Blood 134(Supplement 1):35, 2019.
14. Guillaume Richard-Carpentier, MD , Hagop M. Kantarjian, MD , Nicholas J. Short, MD , Farhad Ravandi, MD , Alessandra Ferrajoli, MD , Heather M Schroeder , Guillermo Garcia-Manero, MD , Guillermo Montalban Bravo, MD , Jorge E. Cortes, MD , Monica Kwari, BSN , Christopher Loiselle, BS , Rebecca Garris, MSc , Nicole Volter, RDC , Nitin Jain, MD , Marina Y Konopleva, MD PhD , Koichi Takahashi, MD , Koji Sasaki, MD , William G. Wierda, MD PhD , Elias Jabbour, MD. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement 1):3807, 2019.
15. Patel K, Michot JM, Chanan-Khan AA, Salles GA, Cartron G, Peyrade F, Bouabdallah R , Reid EG, Thomas SK, Wierda WG, Liebowitz D, Pagel JM, Ribrag V, Saville MW, Johnson CM, Ly T, Phillips TJ. ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement 1):4079, 2019.
16. Tambaro F, Ragoonanan D, Khazal D, Petropoulos D, Tewari P, Kebriaei P, Wierda WG, Kohorst MA, Mahadeo KM. ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement 1):4495, 2019.
17. Furman RR, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Burke K, Covey T , Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, O'Brien SM, Byrd JC. ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement 1):3039, 2019.
18. John N. Allan, MD , Krish Patel, MD , Anthony R. Mato, MDMSCE , William G. Wierda, MD PhD , Javier Pinilla Ibarz, MD PhD , Michael Y. Choi, MD , Susan M. O'Brien, MD , Jeff P. Sharman, MD , Mazyar Shadman, MD , Douglas E Gladstone, MD , Matthew S. Davids, MD , John M. Pagel, MD PhD DSc , Renee Ward, MD PhD , Gary Acton, MD , Pietro Taverna, PhD , Judith A. Fox, PhD , Richard R. Furman, MD , Jennifer R. Brown, MD PhD. Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies. Blood 134(Supplement 1):3041, 2019.
19. Abhishek Maiti, MBBS , Hagop M. Kantarjian, MD , Guillermo Garcia-Manero, MD , Marina Y Konopleva, MD PhD , Srdan Verstovsek, MD PhD , Michael Andreeff, MD PhD , Gautam M. Borthakur, MD , Tapan M. Kadia, MD , Naval G. Daver, MD , Naveen Pemmaraju, MD , Courtney D. DiNardo, MDMSc , Sherry A. Pierce, BSN, BA , Lian-Chun Xiao , Xuelin Huang, PhD , William G. Wierda, MD PhD , Steven M. Kornblau, MD , Farhad Ravandi, MD , Jorge E. Cortes, MD. Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy. Blood 134(Supplement 1):2641, 2019.
20. Vazquez MR , Kantarjian HM, Borthakur GM, O'Brien S, Verstovsek S, Ravandi F, Ferrajoli A, Cortes JE, Kadia TM, |BWierda WG||B, Garcia-Manero G, Dellasala SE, Kehr KA, Pierce SA, Rios MB, Jabbour E. A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy. Blood 134(Supplement 1):2927, 2019.
21. Uri Rozovski, MD , David M. Harris, PhD , Ping Li, PhD , Zhiming Liu, BS , Taghi Manshouri, PhD , Ivo Veletic, MD , Preetesh Jain, MBBS,MDDM,PhD , Alessandra Ferrajoli, MD , Jan A. Burger, MD PhD , Prithviraj Bose, MD , Philip A. Thompson, MBBS , Nitin Jain, MD , Srdan Verstovsek, MD PhD , William G. Wierda, MD PhD , Michael J Keating, MBBS , Zeev E. Estrov, MD. Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells. Blood 134(Supplement 1):3018, 2019.
22. Mazyar Shadman, MD MPH , Kavita Sail, PhD , Beenish S Manzoor, PhD , Maryam Sarraf Yazdy, MD , Brian T. Hill, MD , Hande H. Tuncer, MD , John N. Allan, MD , Chaitra S. Ujjani, MD , Nnadozie Emechebe, MPH , Rajesh Kamalakar, MS , Simon Sharmokh, MPH, PharmD , Daniel Dingfeng Jiang, MD PhD , German Pena, MD , Thomas Marshall, PharmD, MS , Jacqueline Nielsen, PhD , Paul M. Barr, MD , Jennifer R. Brown, MD PhD , Anna Schuh, PhD , Toby A. Eyre, MD , Nicole Lamanna, MD , William G. Wierda, MD PhD , Alan Skarbnik, MD , Lindsey E. Roeker, MD , Rajat Bannerji, MD PhD , James M. Pauff, MD PhD , Stephen J. Schuster, MD , George A Follows, MD PhD , Bruce D. Cheson, MD , Barbara F. Eichhorst, MD , Danielle M. Brander, MD , Irina Pivneva, PhD , Annie Guerin, MSc , Anthony R. Mato, MDMSCE. Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study. Blood 134(Supplement 1):3048, 2019.
23. Uri Rozovski, MD , David M. Harris, PhD , Ping Li, PhD , Zhiming Liu, BS , Taghi Manshouri, PhD , Ivo Veletic, MD , Preetesh Jain, MBBS,MDDM,PhD , Alessandra Ferrajoli, MD , Jan A. Burger, MD PhD , Prithviraj Bose, MD , Philip A. Thompson, MBBS , Nitin Jain, MD , Srdan Verstovsek, MD PhD , William G. Wierda, MD PhD , Michael J Keating, MBBS , Zeev E. Estrov, MD. Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL. Blood 134(Supplement 1):3024, 2019.
24. Ekaterina Kim, MS , Hongying Zhang, MD PhD , Mariela Sivina , Alicia Vaca, PhD , Philip A. Thompson, MBBS , Nitin Jain, MD , Alessandra Ferrajoli, MD , Zeev E. Estrov, MD , Michael J Keating, MBBS , William G. Wierda, MD PhD , William G Rice, PhD , Michael Andreeff, MD PhD , Jan A. Burger, MD PhD. CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells. Blood 134(Supplement 1):3051, 2019.
25. Nicholas J. Short, MD , Hagop M. Kantarjian, MD , Farhad Ravandi, MD , Xuelin Huang, PhD , Naval G. Daver, MD , Courtney D. DiNardo, MD MSc , Marina Y Konopleva, MD PhD , Naveen Pemmaraju, MD , William G. Wierda, MD PhD , Guillermo Garcia-Manero, MD , Koji Sasaki, MD , Jorge E. Cortes, MD , Rebecca Garris, MSc , Marygrace Ward, RDC , Binru Huang, RDC , Corabelle Encarnacion, RDC , Christopher Loiselle, BS , Joseph D. Khoury, MD , Jeffrey L. Jorgensen, MD PhD , Nitin Jain, MD , Joie Alvarez, RN , Nicole Tippett, RN , Susan M. O'Brien, MD , Elias Jabbour, MD. Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood 134(Supplement 1):283, 2019.
26. Nitin Jain, MD , Philip A. Thompson, MBBS , Jan A. Burger, MD PhD , Alessandra Ferrajoli, MD , Koichi Takahashi, MD , Zeev E. Estrov, MD , Gautam M. Borthakur, MD , Prithviraj Bose, MD , Tapan M. Kadia, MD , Naveen Pemmaraju, MD , Koji Sasaki, MD , Naveen Garg, MD , Xuemei Wang, MS , Rashmi Kanagal-Shamanna, MD , Keyur Patel, MD PhD , Jeffrey L. Jorgensen, MD PhD , Sa A Wang, MD , Wanda Lopez, RN , Ana Ayala, RN , William Plunkett, PhD , Varsha Gandhi, PhD , Hagop M. Kantarjian, MD , Susan O'Brien, MD , Michael J Keating, MBBS , William G. Wierda, MD PhD. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53. Blood 134(Supplement 1):357, 2019.
27. Thompson PA, Keating MJ, Jain N, Ferrajoli A, Kadia TM, Bose P, Wierda WG. Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]. Blood 134(Supplement 1):358, 2019.
28. Nitin Jain, MD , Michael J. Keating, MBBS , Philip A. Thompson, MBBS , Jan A. Burger, MD PhD , Alessandra Ferrajoli, MD , Zeev E. Estrov, MD , Gautam M. Borthakur, MD , Koichi Takahashi, MD , Prithviraj Bose, MD , Nathan H. Fowler, MD , Tapan M. Kadia, MD , Naval G. Daver, MD , Marina Y Konopleva, MD PhD , Yesid Alvarado, MD , Musa Yilmaz, MD , Courtney D. DiNardo, MD MSc , Maro Ohanian, DO , Naveen Pemmaraju, MD , Elias Jabbour, MD , Koji Sasaki, MD , Rashmi Kanagal-Shamanna, MD , Keyur Patel, MD PhD , Jeffrey L. Jorgensen, MD PhD , Sa A Wang, MD , Naveen Garg, MD , Xuemei Wang, MS , Katrina Sondermann, BA , Nichole Cruz, RN , Chongjuan Wei, PhD , Ana Ayala, RN , William Plunkett, PhD , Hagop M. Kantarjian, MD , Varsha Gandhi, PhD , William G. Wierda, MD PhD. Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 2019.
29. Erin Parry, MD PhD , Camilla K Lemvigh, MSc , Annabelle J Anandappa, MD , Shuqiang Li, PhD , Lillian Werner, MS , Ana Lako , Noelia Purroy, MD PhD , Satyen H Gohil, PhD, M.B.,B.S. , Giacomo Oliveira, PhD , Pavan Bachireddy, MD , Teddy Huang , Ignaty Leshchiner, PhD , Aina Zurita Martinez , Lars Ronn Olsen, PhD , Kenneth Livak, PhD , Gad Getz, PhD , Donna S Neuberg, ScD , Scott J Rodig, MD PhD , William G. Wierda, MD PhD , Peter Kharchenko, PhD , Nitin Jain, MD , Catherine J. Wu, MD. T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation. Blood, 2019.
30. Mariela Sivina , Gordon Duncan, MSc , Takashi Sakamoto, MD PhD , Ekaterina Kim, MS , Alicia Vaca, PhD , Elena Maria Hartmann, MD , Michael J Keating, MBBS , Alessandra Ferrajoli, MD , William G. Wierda, MD PhD , Tak Mak, PhD DSc , Andreas Rosenwald, MD , Jan A. Burger, MD PhD. Ibrutinib Therapy Downregulates Toso, the Fcr for IgM, Expression in CLL Patients. Blood, 2019.
31. Giacopelli B , Zhao Q, Ruppert A , Agyeman A , Weigel C, Wu YZ, Gerber M , Rabe KG, Larson MC , Lu J , Blachly JS , Rogers KA, Wierda, WG, Brown JR, Rai KR, Keating M , Rassenti LZ , Kipps TJ, Zenz T , Shanafelt TD , Kay NE , Abruzzo LV , Coombes KR , Woyach JA , Byrd JC , Oakes CC. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood 134(8):688-698, 2019.
32. Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Strange M, Nielsen TG, Russell CA.. Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial. Blood 114(22):90, 2009.

Book Chapters

1. Wierda WG, Keating MJ, O'Brien S.. Chronic Lymphocytic Leukemia. In: Cancer: Principles and Practice of Oncology. 8th. Lipppincott Williams & Wilkins: Philadelphia, 2278-2292, 2009.
2. Cortes JE, Kantarjian H., Wierda W. Chronic Leukemias. In: Conn's Current Therapy. W. B. Saunders Company Publications: Pennsylvania, 456-463, 2009.
3. Wierda WG. Gene Therapeutic Approaches for Chronic Lymphocytic Leukemia. In: Unknown, 201-215, 2008.
4. Wierda, WG. Gene Therapy, Vaccines and Immune Modulation. In: Chronic Lymphocytic Leukemia. Informa Healthcare, 2008.